Clinical trials: Somatostatin Receptor Positive
Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer.
- Trial name
- NCT06122610
- Testing
- Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT), Photon Emission Tomography / CT (PET/CT), 64Cu-Dotatate
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Wisconsin, Madison
Neuroendocrine Tumors
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
This is an open-label, single-dose, single-arm, single-center imaging study using DOTATATE peptide, labelled with the 64Cu tracer.
- Trial name
- NCT03673943
- Testing
- 64Cu-DOTATATE
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Radiomedix, Inc.
Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
This phase I trial tests the safety, side effects, and best dose of sunitinib malate in combination with lutetium Lu 177 dotatate in treating patients with pancreatic neuroendocrine tumors.
- Conditions
- Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8, Stage IV Pancreatic Neuroendocrine Tumor AJCC v8
- Trial name
- NCT05687123
- Testing
- Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate
- Where
- 10 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
- Conditions
- Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor
- Trial name
- NCT05636618
- Testing
- [203Pb]VMT-α-NET, [212Pb]VMT-α-NET
- Where
- 20 sites in United States
- Volunteers
- 300 people
- Sponsor
- Perspective Therapeutics
Carcinoma, Neuroendocrine
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
Neuroendocrine tumours (NETs) are rare, slow growing, and diagnosis is often delayed with advanced metastases at presentation. In select patient populations, radioisotope therapy with Lutetium-177 (Lu-DOTA-TATE) has been shown to…
- Trial name
- NCT01876771
- Testing
- [177]Lu-DOTA-TATE
- Where
- Canada
- Volunteers
- 413 people
- Sponsor
- AHS Cancer Control Alberta
Neuroendocrine Tumors, Meningioma
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma
- Trial name
- NCT03273712
- Testing
- 90Y-DOTA tyr3-Octreotide, 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan, Amino Acids
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Iowa
Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
This phase II trial studies how well 177Lu-DOTATATE works in treating patients with rare endocrine cancers that have spread from where they started to nearby tissue or lymph nodes (locally advanced), spread to other places in the…
- Conditions
- Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma
- Trial name
- NCT04106843
- Testing
- Lutetium Lu 177 Dotatate
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy.
- Conditions
- Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms
- Trial name
- LEVEL (NCT05918302)
- Testing
- 177Lu-edotreotide, Everolimus
- Where
- 27 sites in Belgium, France and 2 more
- Volunteers
- 170 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Gastroenteropancreatic Neuroendocrine Tumor
Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
The purpose of this study is to learn about the feasibility and safety of using Peptide Receptor Radionuclide Therapy (PRRT) before and after surgical removal of a tumor.
- Trial name
- NCT04609592
- Testing
- Lutathera, Gallium 68 Dotatate, Computed Tomography (CT)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
The purpose of the current study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive…
- Trial name
- NETTER-3 (NCT06784752)
- Testing
- [177Lu]Lu-DOTA-TATE, Octreotide LAR
- Where
- 67 sites in United States, Canada and 10 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Neuroendocrine Tumors
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Advanced Accelerator Applications is currently pursuing marketing approval for 177Lu-DOTA0-Tyr3-Octreotate (Lutathera). This expanded access therapeutic protocol aims to allow patients suffering from inoperable, somatostatin…
- Trial name
- NCT02705313
- Testing
- 177Lu-DOTA0-Tyr3-Octreotate
- Where
- 41 sites in United States
- Sponsor
- Advanced Accelerator Applications
Neuroendocrine Tumors, Intestinal Neoplasms
Spanish Series of Patients Treated With the Radionuclide Lutetium177
This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of…
- Conditions
- Neuroendocrine Tumors, Intestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms
- Trial name
- SEPTRALU (NCT04949282)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 20 sites in Spain
- Volunteers
- 5,000 people
- Sponsor
- Sociedad Española de Medicina Nuclear e Imagen Molecular
Neuroendocrine Tumors, Carcinoid Tumors
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
This study plans to demonstrate the safety and efficacy of [68Ga]-DOTA-tyr3-Octreotide ([68Ga]-DOTATOC) as an accurate imaging technique for diagnosis, staging, and monitoring of response to treatment in patients with…
- Trial name
- NCT02359500
- Testing
- 68Ga-DOTATOC PET
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Lale Kostakoglu
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NETTER-P (NCT04711135)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Advanced Accelerator Applications
Neuroendocrine Tumors
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
Somatostatin receptor (SSR) imaging is a critical component of clinical care for many patients being investigated for or with confirmed SSR positive tumors.
- Trial name
- NCT04888481
- Testing
- 68Ga-HA-DOTATATE
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- University of Alberta
Neuroendocrine Neoplasm
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
This phase Ib trial is to find out the best dose, possible benefits and/or side effects of peposertib when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors.
- Trial name
- NCT04750954
- Testing
- Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors
Post-Authorization Long-Term Safety Study of LUTATHERA
Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).
- Trial name
- SALUS (NCT03691064)
- Testing
- LUTATHERA
- Where
- 20 sites in United States, France and 3 more
- Volunteers
- 1,014 people
- Sponsor
- Advanced Accelerator Applications
Breast Cancer Stage IV
Study of Dotatate Imaging in Breast Cancer
This will be a Phase 2 clinical trial to assess somatostatin receptor (SSTR) expression in Stage IV estrogen receptor positive (ER+) breast cancer using Gallium-68 DOTATATE or Copper-64 DOTATATE PET/CT.
- Trial name
- NCT05880394
- Testing
- Gallium-68 DOTATATE, Copper-64 DOTATATE
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hoag Memorial Hospital Presbyterian
Neuroendocrine Tumors, Paraganglioma
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
Peptide receptor radionuclide therapy (PRRT) may be recommended in G1- G2 GEP-NET patients with disease progression on somatostatine analogues therapy (LUTATHERA®).
- Conditions
- Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma
- Trial name
- LUFOR (NCT06045260)
- Testing
- 177Lu-DOTATOC
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS